Tyco cancels proposed breakup of company:
This article was originally published in Clinica
Tyco International shares dropped to below $20 - its lowest level in around four years - after the company yesterday abandoned plans to split into four separate businesses. The conglomerate announced the proposed split in January (see Clinica No 993, p 15). Chairman and CEO Dennis Kozlowski said in a letter to shareholders: "But we now know it was a mistake and it is time for us to return our focus to what we do best."
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.